Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer
Mercedes Marín‐Aguilera(Oryzon Genomics (Spain)), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Phillip Michaels(Brigham and Women's Hospital), Kornélia Polyák(Dana-Farber Cancer Institute), Judit Matito(Oryzon Genomics (Spain)), Oleguer Castillo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), P. Blasco(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Ian E. Krop(Yale Cancer Center), Olivia Gordon, Francisco José Pena Pardo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Lily Moon, Blanca González‐Farré(Hospital Clínic de Barcelona), Thilini Hemali Senevirathne(Brigham and Women's Hospital), Paul T. Spellman(Oregon Health & Science University), Julien Curaba, Joel S. Parker(University of North Carolina at Chapel Hill), Danielle K. Manning(Brigham and Women's Hospital), A.G. Waks(Brigham and Women's Hospital), Patricia Galván(Vall d'Hebron Institute of Oncology), Ana Isabel Martínez-Puchol(Hospital Clínic de Barcelona), Charles M. Perou(University of North Carolina at Chapel Hill), Olga Martínez‐Sáez(Breast Cancer Research Foundation), V. Sirenko(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Esther Sanfeliu(Hospital Clínic de Barcelona), Ana Vivancos(Vall d'Hebron Institute of Oncology), Andrew J. Aguirre(Broad Institute), Patricia Villagrasa, Catherine Nee(Brigham and Women's Hospital), Aleix Prat(Hospital Clínic de Barcelona), Joan Anton Puig‐Butillé(Hospital Clínic de Barcelona), J.A. Abery, P. Wachirakantapong(Brigham and Women's Hospital), E. Hernández-lllán(Hospital Clínic de Barcelona), Zhongyi Li(Harvard University), S. Shankar(Brigham and Women's Hospital), F. Brasó-Maristany(Breast Cancer Research Foundation), William Buckingham(Oryzon Genomics (Spain)), Pedro Jares(Hospital Clínic de Barcelona)
Cited by 27
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
|Nature reviews. Cancer|2009|3.3k